News stories about Edge Therapeutics (NASDAQ:EDGE) have trended somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Edge Therapeutics earned a coverage optimism score of 0.07 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 42.1999135152279 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:
- FDA Approves Galafold™ (migalastat) for the Treatment of Certain Adult Patients with Fabry Disease (markets.businessinsider.com)
- Global Epilepsy Therapeutics Market Will Reach USD 5,900 Million by 2024: Zion Market Research (globenewswire.com)
- Sarepta Therapeutics Announces Second Quarter 2018 Financial Results and Recent Corporate Developments (forextv.com)
- Rounds Report: Spark Therapeutics Ironically Topped Our Featured List Despite Its Depreciation (seekingalpha.com)
- Pain Therapeutics’ opioid drug fails to gain FDA approval (pharmaphorum.com)
Separately, ValuEngine raised Edge Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. One research analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $14.50.
NASDAQ EDGE traded down $0.02 during trading hours on Friday, hitting $0.91. 148,487 shares of the company traded hands, compared to its average volume of 181,691. Edge Therapeutics has a twelve month low of $0.84 and a twelve month high of $17.77.
Edge Therapeutics (NASDAQ:EDGE) last issued its quarterly earnings results on Thursday, August 2nd. The biotechnology company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.12.
About Edge Therapeutics
Edge Therapeutics, Inc, a clinical-stage biotechnology company, discovers, develops, and seeks to commercialize hospital-based therapies for acute life-threatening neurological and other conditions. Its lead product includes EG-1962, a polymer-based microparticle used for the treatment of aneurysmal subarachnoid hemorrhage.
See Also: Understanding Stock Ratings
Receive News & Ratings for Edge Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.